Current research focuses on the potential utility of HDAC inhibitors as monotherapy or in combination with other chemotherapeutic regimens in NSCLC, with the aim of improving their efficacy or decreasing tumor resistance. This evidence concerns the gene HDAC9 and neoplasm.